10
MNiSW
71.22
ICV
REVIEW PAPER
 
CC BY-NC-ND 3.0
 
 

Aliskiren – an antihypertensive renin inhibitor in the treatment of patients with chronic kidney disease

 
1
Department of Physiopathology, Institute of Rural Health, Lublin, Poland
2
Department of Pathophysiology, Medical University, Lublin, Poland
3
Department of Nephrology, Medical University, Lublin, Poland
JPCCR 2017;11(1):81–85
KEYWORDS:
ABSTRACT:
Introduction:
The renin-angiotensin-aldosterone system (RAAS) plays an important role in the pathogenesis of hypertension, cardiovascular diseases (CVDs) and chronic kidney disease (CKD). Drugs affecting the RAAS system, such as angiotensinconverting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), are commonly used in the treatment of hypertension and heart failure. These drugs are also effective in reducing proteinuria and may, at least, delay end-stage renal disease in both diabetic and non-diabetic proteinuric CKD. However, novel drugs are needed to more effectively suppress the RAAS system and the progression of CKD. Aliskiren is the first direct renin inhibitor which has been approved for the treatment of hypertension. Additionally, a number of clinical studies have shown the antiproteinuric effect of aliskiren.

Objective:
This review focuses on the antihypertensive and antiproteinuric effects of aliskiren in patients with CKD. The pharmacology of aliskiren in these patients is also provided.

Conclusions:
Aliskiren-based hard endpoint large trials in non-diabetic nephropathy are needed in order to clarify the use of aliskiren in CKD patients.

CORRESPONDING AUTHOR:
Krzysztof Łukawski
Department of Physiopathology, Institute of Rural Health, Lublin, Poland
 
REFERENCES (46):
1. WHO. Cardiovascular diseases (CVDs). Fact sheet N°317, March 2013.
2. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000; 35(4 Suppl 1): S117‒131.
3. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3: 1‒150.
4. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382(9888): 260‒272.
5. Johnston CI: Biochemistry and pharmacology of the renin-angiotensin system. Drugs. 1990; 39(Suppl 1): 21‒31.
6. Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, Boas WW, Dos Santos RA, Simões e Silva AC. The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag. 2008; 4(4): 787‒803.
7. Laragh JH, Case DB, Atlas SA, Sealey JE. Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effects on blood pressure and its use to identify and treat the renin factor. Hypertension. 1980; 2(4): 586‒593.
8. Dávalos M, Frega NS, Saker B, Leaf A. Effect of exogenous and endogenous angiotensin II in the isolated perfused rat kidney. Am J Physiol. 1978; 235(6): F605‒610.
9. Blantz RC, Gabbai FB. Effect of angiotensin II on glomerular hemodynamics and ultrafiltration coefficient. Kidney Int Suppl. 1987; 20: S108‒111.
10. Farsang C. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag. 2011; 7: 605‒622.
11. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000; 52(3): 415‒472.
12. Thind GS. Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics. Cardiovasc Drugs Ther. 1990; 4(1): 199‒206.
13. Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol. 2012; 23(12): 1917‒1928.
14. Gentile G, Remuzzi G, Ruggenenti P. Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny. Nephron. 2015; 129(1): 39‒41.
15. Persson F, Rossing P. Sequential RAAS blockade: is it worth the risk? Adv Chronic Kidney Dis. 2014; 21(2): 159‒165.
16. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008; 47(8): 515‒531.
17. Sanoski CA. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension. Pharmacotherapy. 2009; 29(2): 193‒212.
18. Buczko W, Hermanowicz JM. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep. 2008; 60(5): 623‒631.
19. Vaidyanathan S, Bigler H, Yeh C, Bizot MN, Dieterich HA, Howard D, Dole WP. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet. 2007; 46(8): 661‒675.
20. Morishita Y, Kusano E. Direct Renin inhibitor: aliskiren in chronic kidney disease. Nephrourol Mon. 2013; 5(1): 668‒672.
21. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, Schalkwijk C, Boomsma F, Frandsen E, Parving HH. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008; 73(12): 1419‒1425.
22. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358(23): 2433‒2446.
23. Ito S, Nakura N, Le Breton S, Keefe D. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens Res. 2010; 33(1): 62‒66.
24. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AH, Boomsma F, Frandsen E, Parving HH. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia. 2010; 53(8): 1576‒1580.
25. Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res. 2011; 34(3): 308‒313.
26. Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant. 2011; 26(9): 2930‒2934.
27. Moriyama T, Tsuruta Y, Kojima C, Itabashi M, Sugiura H, Takei T, Ogawa T, Uchida K, Tsuchiya K, Nitta K. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. Int Urol Nephrol. 2012; 44(3): 841‒845.
28. Nakamura T, Sato E, Amaha M, Kawagoe Y, Maeda S, Yamagishi S. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. J Renin Angiotensin Aldosterone Syst. 2012; 13(1): 122‒127.
29. Lizakowski S, Tylicki L, Renke M, Rutkowski P, Heleniak Z, Sławińska- Morawska M, Aleksandrowicz E, Łysiak-Szydłowska W, Rutkowski B. Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial. Int Urol Nephrol. 2012; 44(6): 1763‒1770.
30. Tang SC, Lin M, Tam S, Au WS, Ma MK, Yap DY, Ho YW, Lai KN. Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrol Dial Transplant. 2012; 27(2): 613‒618.
31. Abe M, Suzuki H, Okada K, Maruyama N, Inoshita A, Baba S, Takashima H, Soma M. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. Heart Vessels. 2013; 28(4): 442‒452.
32. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012; 367(23): 2204‒2213.
33. Woo KT, Choong HL, Wong KS, Tan HK, Foo M, Stephanie FC, Lee EJ, Anantharaman V, Lee GS, Chan CM. A retrospective aliskiren and losartan study in non-diabetic chronic kidney disease. World J Nephrol. 2013; 2(4): 129‒135.
34. Woo KT, Choong HL, Wong KS, Tan HK, Foo M, Fook-Chong S, Lee EJ, Anantharaman V, Lee GS, Chan CM. Aliskiren and losartan trial in non-diabetic chronic kidney disease. J Renin Angiotensin Aldosterone Syst. 2014; 15(4): 515‒522.
35. Ohsawa M, Tamura K, Kanaoka T, Wakui H, Maeda A, Dejima T, Azushima K, Uneda K, Kobayashi R, Tsurumi-Ikeya Y, Toya Y, Fujikawa T, Umemura S. Addition of aliskiren to angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease. Int J Mol Sci. 2013; 14(8): 15361‒15375.
36. Wu MT, Tung SC, Hsu KT, Lee CT. Aliskiren add-on therapy effectively reduces proteinuria in chronic kidney disease: an open-label prospective trial. J Renin Angiotensin Aldosterone Syst. 2014; 15(3): 271‒277.
37. Kuriyama S, Yokoyama K, Hara Y, Sugano N, Yokoo T, Hosoya T. Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. Clin Exp Nephrol. 2014; 18(5): 821‒830.
38. Soji K, Doi S, Nakashima A, Sasaki K, Kawai T, Aoki A, Kyuden Y, Fujiwara K, Yokoyama Y, Masaki T. Efficacy of add-on therapy of aliskiren to an angiotensin II receptor blocker on renal outcomes in advanced-stage chronic kidney disease: a prospective, randomized, open-label study. Clin Exp Nephrol. 2015; 19(4): 631‒638.
39. Tani S, Kushiro T, Takahashi A, Kawamata H, Ohkubo K, Nagao K, Hirayama A. Antihypertensive efficacy of the direct renin inhibitor aliskiren as add-on therapy in patients with poorly controlled hypertension. Intern Med. 2016; 55(5): 427‒435.
40. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005; 111(8): 1012‒1018.
41. O’Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007; 49(2): 276‒284.
42. Teo KK, Pfeffer M, Mancia G, O’Donnell M, Dagenais G, Diaz R, Dans A, Liu L, Bosch J, Joseph P, Copland I, Jung H, Pogue J, Yusuf S; Aliskiren Prevention of Later Life Outcomes trial Investigators. Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. Eur Heart J. 2014; 35(26): 1743‒1751.
43. Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013; 309(11): 1125‒1135.
44. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129‒2200.
45. https://nadcisnienietetnicze.pl/ptnt/wytyczne_ptnt.
46. http://www.ema.europa.eu/docs/en_GB/document_library/Press_ release/2012/02/WC500122913.pdf.
Copy url
Share
 
 
eISSN:1898-7516
ISSN:1898-2395